Peak Bio, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Peak Bio, Inc. (PKBO) is a clinical-stage biopharmaceutical company that develops therapeutics addressing unmet medical needs in oncology and inflammation. The company offers a pipeline featuring an antibody-drug conjugate (ADC) platform incorporating its proprietary PH-1 (Thailanstatin) spliceosome modulator toxin, novel linkers, and cancer-targeting antibodies for solid tumors; PHP-303, a Phase 2-ready oral small molecule neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency (AATD) and potential acute respiratory distress syndrome (ARDS) applications; and additional preclinical ADC candidates combining cytotoxic payloads with immune-stimulating mechanisms. Peak Bio targets patients with cancer, rare genetic disorders, inflammatory diseases, and specialty conditions, operating primarily in the United States with research sites supporting its biotechnology efforts. Founded in 2015 and headquartered in Palo Alto, California, the company maintains a lean operation with approximately six employees and focuses on innovative small molecules, antibodies, and ADCs. In November 2024, Peak Bio completed a merger with Akari Therapeutics, Plc, becoming its wholly-owned subsidiary in an all-stock transaction that resulted in approximately 50/50 ownership split, enhanced pipeline diversification including geographic atrophy assets, and concurrent $3.2 million private placement financing; the combined entity trades as Akari (AKTX) on Nasdaq. This strategic combination followed earlier equity arrangements, including a 2022 up-to-$100 million common stock purchase agreement with White Lion Capital and a planned SPAC merger with Ignyte Acquisition Corp., bolstering capital for clinical milestones and ADC advancement. Peak Bio continues to pursue collaborations for its differentiated Trop2 PH-1 ADC and novel payloads amid ongoing patent filings and preclinical progress.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Peak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicing
Peak Bio, Inc. Announces Up-listing to OTCQB Market
Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors
Peak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion Capital
Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting
What Is Going on With Peak Bio (PKBO) Stock Today?